Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amgen (AMGN)

Amgen says Chief Technology Officer David Reese to retire June 30, 2026

Neutral Impact 3 of 5 leadership Written later

Amgen said Executive Vice President and Chief Technology Officer David M. Reese will retire on June 30, 2026. His technology responsibilities move to three executives effective June 1, 2026, and the company named Sean Bruich as senior vice president and Chief Technology Officer.

Key points

  • Reese retires as Executive Vice President on June 30, 2026, and will receive retirement benefits under company plans.
  • Effective June 1, 2026, James E. Bradner, Murdo Gordon and Chief Financial Officer Peter H. Griffith take over the CTO role's responsibilities.
  • Sean Bruich will serve as senior vice president and Chief Technology Officer, effective June 1, 2026, according to the press release.
  • The filing gives no financial figures for the change, and the company describes it as part of a move to integrate science and technology.

The filing

CompanyAmgen (AMGN)
Form8-K, current report
Filed with the SECApr 22, 2026, 4:03 PM ET
Accession number0000318154-26-000048

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 22, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.